REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > O-glycoside > Polysaccharide > Heparin Or Derivative Heparin Or DerivativeHeparin Or Derivative patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.01/25/07 - 20070021378 - Heparin compositions and selectin inhibition The disclosure provides in vitro and in vivo methods for identifying Heparins and Heparinoids that modulate the activity of selecting. The disclosure also provides Heparins and Heparinoids that modulate the activity of selecting. The identification and isolation of these heparin formulations has the potential to mediate a wide variety of ... 01/04/07 - 20070004673 - Administration of enoxaparin sodium to patients with severe renal impairment Methods having novel enoxaparin sodium dosing regimens for patients with severe renal impairment are disclosed. The methods may be used for one or more of preventing thrombotic episodes, treating thrombotic episodes, preventing postoperative venous thrombosis, controlling thrombosis and/or decreasing blood hypercoagulation and/or hemorrhaging risks, treating unstable angina, and treating non-Q-wave ... 12/28/06 - 20060293279 - Administration of enoxaparin sodium to patients with severe renal impairment Methods having novel enoxaparin sodium dosing regimens for patients with severe renal impairment are disclosed. The methods may be used for one or more of preventing thrombotic episodes, treating thrombotic episodes, preventing postoperative venous thrombosis, controlling thrombosis and/or decreasing blood hypercoagulation and/or hemorrhaging risks, treating unstable angina, and treating non-Q-wave ... 08/17/06 - 20060183713 - Compositions of low molecular weight heparin produced with modified heparinase iii The invention relates to heparinase III and mutants thereof. Modified forms of heparinase III having reduced enzymatic activity which are useful for a variety of purposes, including sequencing of heparin-like glycosaminoglycans (HLGAGs), removing active heparan sulfate from a solution, inhibition of angiogenesis, etc. have been discovered according to the invention. ... 08/17/06 - 20060183712 - Affinity purified heparin/heparan sulfate for controlling the biological activity of the fgf receptor Methods and compositions for modulating the activity of a FGF receptor in a mammal are disclosed. The methods and compositions utilize substantially purified heparin/heparan sulfate oligosaccharides (HS) that have high affinity for FGF7. HS that has high affinity for FGF7 has increased activity for promoting the formation of a ternary ... 06/15/06 - 20060128657 - Selected betaines and their uses A physiologically acceptable, sterile and pyrogen-free solution of betaine dissolved in a physiologically acceptable solvent, having a pH adjusted to from 5.0 to 8.0 with a betaine concentration of from 5 to 500 mg/ml. ... 06/08/06 - 20060122152 - Heparin for the treatment of ocular pathologies Formulations and methods useful to treat ocular neovascularization (new blood vessel growth in the cornea, retina, conjunctiva, and/or choroid) are illustrated. According to the invention there is provided a formulation suitable for the treatment of ocular neovascularization that may comprise heparin in a concentration and dose suitable for treating ocular ... 06/01/06 - 20060116350 - Dopamine 3 receptor agonist and antagonist treatment of gastrointestinal motility disorders The invention discloses that systemic activation of dopamine 3 receptor (D3R) significantly delays gastric emptying in rat, suggesting that D3R plays an important role in the regulation of gastric motility. Specific D3R antagonist, nafadotride, was shown to partially reverse the effect of dopamine on gastric emptying. The invention also discloses ... 05/25/06 - 20060111317 - Rapid two-step synthesis of anti-coagulants The present invention provides methods for the production of N-deacetylate N-sulfate derivatives of non-sulfated N-acetyl heparosan (HS) polysaccharides, compounds thus obtained and compositions comprising same. This invention also provides applications of N-deacetylate N-sulfate derivatives of non-sulfated N-acetyl heparosan (HS) polysaccharides, and compositions comprising same, for use in controlling coagulation and ... 05/11/06 - 20060100175 - Novel therapeutic use of low molecular weight heparins The invention concerns the use of low molecular weight heparin for preventing and/or treating motor neuron diseases. ... 05/04/06 - 20060094690 - Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin The present invention relates to inhibiting or preventing infection and protecting against patency complications after a blood catheter has been inserted in a patient comprising administering to the device a pharmaceutically effective amount of a composition comprising: (A) at least one taurinamide derivative, (B) at least one compound selected from ... 04/13/06 - 20060079483 - Heparin oligosaccharides The present invention provides composition and methods for the synthesis of low molecular weight heparins and heparinoids. The present invention also provides compositions having substantially homogenous populations of desired heparin molecules, or molecules useful in the synthesis of heparin oligosaccharides. ... 02/23/06 - 20060040896 - Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity A method and medicament for anticoagulating a patient with a sulfated polysaccharide mixture that demonstrates enhanced anti-inflammatory activity compared to anticoagulation with unfractionated heparin comprising various combinations of fully anticoagulant unfractionated heparin with 2-O desulfated heparin demonstrating reduced anticoagulant activity but enhanced anti-inflammatory actions. The medicament preferably is administered intravenously, ... 01/19/06 - 20060014720 - Heparin prodrugs and drug delivery stents formed therefrom A prodrug comprising a heparin and a drug is provided. The prodrug can be used to form a coating on a medical device. The prodrug can also be used with a polymeric material to form a coating on a medical device. The polymeric material can be a hydrophobic polymer, a ... 12/29/05 - 20050288252 - Composition for stimulating bone growth and differentiation and method for isolating same This invention relates to isolated heparan sulphate and use thereof to stimulate bone cell growth and differentiation. The invention also relates to use of heparan sulphate with implants, prosthesis and bioscaffolds to repair and regenerate bone. Such use may be for repair of damaged tissue including bone tissue, for example ... 12/29/05 - 20050288251 - Treatment and prevention of abnormal cellular proliferation This invention provides a method for inhibiting or preventing the abnormal growth of cells, including transformed cells, by administering an effective amount of O-acylated heparin derivative. Abnormal growth of cells refers to cell growth independent of normal regulatory mechanism (e.g. loss of contact inhibition). This includes the abnormal growth of: ... 12/22/05 - 20050282775 - Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome A method and medicament for treating inflammation in a patient with a sulfated polysaccharide without inducing platelet activation or thrombosis in the presence of heparin- and platelet factor 4-complex reactive antibodies using a 2-O desulfated heparin with an average degree of sulfation of 0.6 sulfate groups per monosaccharide or greater ... 12/01/05 - 20050267070 - Process for the preparation of esters of heparin The description relates to a process for the production of esters of heparin, wherein from 0.1 to 2 g of a halogenated reagent having the formula R—CH2—X, where R is a phenyl group which is non-substituted or substituted by a halogen atom or by a nitro group, and X is ... 11/24/05 - 20050261243 - Antiprostaglandins for the treatment of ocular pathologies Formulations and methods useful to treat ocular neovascularization (new blood vessel growth in the cornea, retina, conjunctiva, and/or choroid) are disclosed. According to the invention there is provided a formulation suitable for the treatment of ocular neovascularization that may comprise flurbiprofen in a concentration and dose suitable for treating ocular ... 11/24/05 - 20050261242 - Pharmaceutical compounds wherein: A is a drug radical; B is a linker; and C is a bivalent radical. ... 11/17/05 - 20050256081 - Tetracycline derivatives for the treatment of ocular pathologies Formulations and methods useful to reduce ocular neovascularization (new blood vessels in the cornea, retina, conjunctiva, and/or choroid) are disclosed. According to the invention the formulation will include tetracycline or a derivative thereof including chemically modified tetracyclines (CMT) which inhibit matrix metalloproteinase (MMP) activity at a substantially neutral pH in ... 10/20/05 - 20050234015 - Low molecular weight heparin salt with triethanolamine useful as therapeutic-antitrombotic agent of local delivery, procedures for preparing them, process for elimination of hygroscopicity of heparin salt, pharmaceutical compositions for local use in anti Low molecular weight heparin salt with triethanolamine useful as a therapeutic-antithrombotic agent for local delivery, having at least 60% of its total mass a molecular weight of less than 8000 Da and an average molecular weight from 4000 to 6000 Da, said salt also having a content of organic sulfur ... 10/06/05 - 20050222084 - Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect where the U, R and R1 groups have the meanings indicated in the description. These glycosaminoglycan derivatives exhibit antiangiogenic activity and are devoid of anticoagulant activity. ... 09/29/05 - 20050215519 - Process for oxidizing unfractionated heparins and detecting presence or absence of glycoserine in heparin and heparin products The invention provides a process for preparing heparin products with a reduced content of glycoserine. A method for detecting glycoserine in preparations of heparin is also provided. ... 09/15/05 - 20050203059 - Methods and compositions for treatment of ischemia Methods and compositions are provided for the prophylaxis or inhibition of cerebral ischemic injury by administration of an inhibitor of glycogen synthase kinase 3 (GSK3) activity, either alone or in combination with at least one additional agent for the treatment of ischemic stroke. ... 09/01/05 - 20050192252 - Administration of enoxaparin sodium to patients with severe renal impairment Methods having novel enoxaparin sodium dosing regimens for patients with severe renal impairment are disclosed. The methods may be used for one or more of preventing thrombotic episodes, treating thrombotic episodes, preventing postoperative venous thrombosis, controlling thrombosis and/or decreasing blood hypercoagulation and/or hemorrhaging risks, treating unstable angina, and treating non-Q-wave ... 08/04/05 - 20050171055 - Compositions of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them Alkali and alkali-earth metal salts of polysaccharides derived from heparin, their method of preparation and the pharmaceutical compositions containing them. ... 07/28/05 - 20050164985 - Therapeutic application of enoxaparin The present invention relates to the use of enoxaparin for treating a disease linked to the modulation of heparanase activity. ... 07/14/05 - 20050153930 - Inhibition of a novel calcium injury current that forms in nuerons during injury prevents neuronal cell death Calcium channels which form in neuronal membranes in response to injury are disclosed. Methods and compositions for blocking this injury induced calcium channel and preventing further injury to neuronal cells and/or neuronal cell death are disclosed. The compositions and methods disclosed may be used to alleviate acute or chronic injury ... 06/23/05 - 20050137167 - Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect Partially desulphated glycosaminoglycan derivatives are described, particularly heparin, and more particularly formula (I) compounds where the U, R and R1 groups have the meanings indicated in the description. Said glycosaminoglycan derivatives are endowed with antiangiogenic and heparanase-inhibiting activity ans are devoid of anticoagulant activity. ... ### FreshPatents.com Support |